Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (Zen-Zen Biotech)
- Development stage
- Preclinical
- Lead developer
- ZenZen Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Intrathecal
01
Overview
Wharton's jelly-derived mesenchymal stem cells (UCMSCs) from ZenZen Biotech are a multipotent stem cell therapy harvested from the umbilical cord. These cells are utilized for their regenerative and immunomodulatory properties, which are mediated primarily through paracrine signaling. By secreting a variety of cytokines, growth factors, and exosomes, UCMSCs can modulate the immune system, reduce inflammation, and promote tissue repair across a wide range of clinical applications. ZenZen Biotech, a Taiwanese biotechnology firm, offers these cells for the treatment of neurodegenerative diseases, cardiovascular conditions, autoimmune disorders, and musculoskeletal injuries, as well as for anti-aging and rejuvenation purposes. The company also provides long-term storage services for these umbilical cord-derived stem cells.
- Other names
- Umbilical cord mesenchymal stem cellsWharton's jelly mesenchymal stem cells
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (Zen-Zen Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (Zen-Zen Biotech).